ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1263

Applications of Protein Microarray for Saliva Diagnostics in Autoimmune Diseases

Yeon-Ah Lee1, Yong-Gil Kim2, Seung-Jae Hong1 and Paul J. Utz3, 1Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 3Medicine, Stanford University School of Medicine, Stanford, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Antibody microarray, Mixed connective tissue disease (MCTD), proteomics and salivary gland, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

There have been many reports showing that saliva could be a source of biomarkers capable of detecting certain diseases. However, very few studies have been conducted to profile autoantibody isotypes in the saliva of various autoimmune diseases except Sjogren’s syndrome. This study was performed to establish protein microarray for saliva diagnostics in autoimmune diseases and to identify distinct profiles of salivary autoantibody in patients with systemic lupus erythematosus (SLE). 

Methods:

We constructed antigen microarrays and probed healthy saliva spiked with commercial antibodies (Abs) (monoclonal mouse anti-La, anti-Ro52 and anti-Ro60 and polyclonal rabbit anti-U1-70). To investigate whether saliva destroys Abs existing in patients’ serum, we used serum from clinically confirmed SLE and mixed connective tissue disease (MCTD) patients diluted from 250 to 8000 fold with healthy saliva and PBST containing 5% fetal calf serum. Following proof-of-concept experiments, we developed another array with a panel of canonical antigens of SLE as well as cytokines (interferon α-2b, interferon γ, BAFF and CXCL13) to characterize autoantibodies in matched saliva and serum derived from 17 SLE patients and 13 healthy controls. The autoantibody IgG and IgA isotypes were assayed using goat anti-human IgG (AF647 conjugated) and goat anti-human IgA (Cy3 conjugated). The Axon Scanner and GenePix Pro 7.0 were used to determine median fluorescence intensities (MFI) of features and background. Data were analyzed using MultiExperiment Viewer and Significance Analysis of Microarray (SAM) algorithm.

Results:

The dynamic range of detection on the array was 1-104 ng/mL for commercial Abs spiked into saliva. We observed a high degree of specificity and each Ab was specific for its target antigen. In the experiments investigating the effect of saliva on the reactivity of Abs existing in patients’ serum (anti-Ro52 and anti-La in SLE, anti-U1-70 and anti-U1-A in MCTD), saliva made the MFI signals a little bit weaker than buffer, but it was not significantly different. The optimal dilution rate of saliva for protein microarray turned out to be 1:4 to 1:8. Matched saliva and serum samples from 17 SLE patients and healthy controls were incubated with anti-IgG and anti-IgA secondary Abs.  IgG Ab reactivity against specific antigens was found mainly in serum, while IgA Ab reactivity to given antigens was predominant in saliva, suggesting the possibility of isotype switching between saliva and serum. SAM identified 7 antigens including BAFF, Ro60, U1-A and Sm/RNP that were significantly more reactive to IgA Ab in the saliva of SLE patients than in healthy controls (false discovery rate<0.01). The hierarchical clustered heat-map successfully placed SLE patients into close subgroups.

Conclusion:

Protein microarrays facilitate detection of autoantibody in human saliva as well as serum. Saliva profiling revealed that elevated IgA autoantibody reactivity to several targets including BAFF was associated with SLE compared with controls. The noninvasive nature of saliva collection with protein microarray highlights the efficacy of pursuing saliva as a diagnostic medium.


Disclosure: Y. A. Lee, None; Y. G. Kim, None; S. J. Hong, None; P. J. Utz, None.

To cite this abstract in AMA style:

Lee YA, Kim YG, Hong SJ, Utz PJ. Applications of Protein Microarray for Saliva Diagnostics in Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/applications-of-protein-microarray-for-saliva-diagnostics-in-autoimmune-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/applications-of-protein-microarray-for-saliva-diagnostics-in-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology